nodes	percent_of_prediction	percent_of_DWPC	metapath
Probenecid—ABCC11—Methotrexate—urinary bladder cancer	0.0614	0.0782	CbGbCtD
Probenecid—ABCC6—Cisplatin—urinary bladder cancer	0.0543	0.0692	CbGbCtD
Probenecid—ABCC6—Etoposide—urinary bladder cancer	0.0534	0.068	CbGbCtD
Probenecid—ABCC5—Fluorouracil—urinary bladder cancer	0.0489	0.0622	CbGbCtD
Probenecid—ABCC5—Cisplatin—urinary bladder cancer	0.0415	0.0529	CbGbCtD
Probenecid—ABCC6—Doxorubicin—urinary bladder cancer	0.0364	0.0464	CbGbCtD
Probenecid—ABCC3—Fluorouracil—urinary bladder cancer	0.0307	0.0391	CbGbCtD
Probenecid—SLCO1C1—Methotrexate—urinary bladder cancer	0.027	0.0343	CbGbCtD
Probenecid—SLC16A1—Methotrexate—urinary bladder cancer	0.027	0.0343	CbGbCtD
Probenecid—ABCC3—Cisplatin—urinary bladder cancer	0.0261	0.0332	CbGbCtD
Probenecid—ABCC3—Etoposide—urinary bladder cancer	0.0257	0.0327	CbGbCtD
Probenecid—SLC22A7—Fluorouracil—urinary bladder cancer	0.024	0.0306	CbGbCtD
Probenecid—ABCC4—Fluorouracil—urinary bladder cancer	0.0235	0.0299	CbGbCtD
Probenecid—ABCC1—Epirubicin—urinary bladder cancer	0.0202	0.0257	CbGbCtD
Probenecid—ABCB1—Mitomycin—urinary bladder cancer	0.0185	0.0235	CbGbCtD
Probenecid—ABCC3—Doxorubicin—urinary bladder cancer	0.0175	0.0223	CbGbCtD
Probenecid—ABCC3—Methotrexate—urinary bladder cancer	0.0169	0.0216	CbGbCtD
Probenecid—ABCC1—Etoposide—urinary bladder cancer	0.0157	0.0201	CbGbCtD
Probenecid—SLC22A2—Cisplatin—urinary bladder cancer	0.0145	0.0185	CbGbCtD
Probenecid—SLC22A11—Methotrexate—urinary bladder cancer	0.0139	0.0177	CbGbCtD
Probenecid—ABCC2—Carboplatin—urinary bladder cancer	0.0139	0.0177	CbGbCtD
Probenecid—SLC22A7—Methotrexate—urinary bladder cancer	0.0133	0.0169	CbGbCtD
Probenecid—ABCC4—Methotrexate—urinary bladder cancer	0.0129	0.0165	CbGbCtD
Probenecid—ABCC2—Cisplatin—urinary bladder cancer	0.0119	0.0151	CbGbCtD
Probenecid—ABCC2—Etoposide—urinary bladder cancer	0.0117	0.0148	CbGbCtD
Probenecid—ABCC1—Doxorubicin—urinary bladder cancer	0.0107	0.0137	CbGbCtD
Probenecid—ABCC1—Methotrexate—urinary bladder cancer	0.0104	0.0132	CbGbCtD
Probenecid—SLCO1A2—Methotrexate—urinary bladder cancer	0.00929	0.0118	CbGbCtD
Probenecid—ALB—Fluorouracil—urinary bladder cancer	0.0087	0.0111	CbGbCtD
Probenecid—CYP3A4—Thiotepa—urinary bladder cancer	0.0084	0.0107	CbGbCtD
Probenecid—SLC22A8—Methotrexate—urinary bladder cancer	0.00809	0.0103	CbGbCtD
Probenecid—ABCC2—Doxorubicin—urinary bladder cancer	0.00795	0.0101	CbGbCtD
Probenecid—ABCC2—Methotrexate—urinary bladder cancer	0.0077	0.00981	CbGbCtD
Probenecid—CYP2C8—Fluorouracil—urinary bladder cancer	0.00673	0.00856	CbGbCtD
Probenecid—SLC22A6—Methotrexate—urinary bladder cancer	0.00564	0.00718	CbGbCtD
Probenecid—CYP2C8—Etoposide—urinary bladder cancer	0.00561	0.00715	CbGbCtD
Probenecid—ABCB1—Gemcitabine—urinary bladder cancer	0.00532	0.00678	CbGbCtD
Probenecid—ALB—Methotrexate—urinary bladder cancer	0.0048	0.00611	CbGbCtD
Probenecid—CYP2C9—Fluorouracil—urinary bladder cancer	0.00469	0.00597	CbGbCtD
Probenecid—CYP2C9—Cisplatin—urinary bladder cancer	0.00399	0.00507	CbGbCtD
Probenecid—ABCB1—Cisplatin—urinary bladder cancer	0.00387	0.00492	CbGbCtD
Probenecid—ABCB1—Etoposide—urinary bladder cancer	0.0038	0.00484	CbGbCtD
Probenecid—PANX1—prostate gland—urinary bladder cancer	0.00347	0.0438	CbGeAlD
Probenecid—SLC2A9—prostate gland—urinary bladder cancer	0.00314	0.0398	CbGeAlD
Probenecid—SLC22A12—renal system—urinary bladder cancer	0.00312	0.0394	CbGeAlD
Probenecid—PANX1—seminal vesicle—urinary bladder cancer	0.00293	0.0371	CbGeAlD
Probenecid—SLC2A9—seminal vesicle—urinary bladder cancer	0.00266	0.0336	CbGeAlD
Probenecid—ABCB1—Doxorubicin—urinary bladder cancer	0.00259	0.0033	CbGbCtD
Probenecid—ABCC6—Podofilox—Etoposide—urinary bladder cancer	0.00258	1	CbGdCrCtD
Probenecid—ABCB1—Methotrexate—urinary bladder cancer	0.00251	0.0032	CbGbCtD
Probenecid—SLC22A8—urine—urinary bladder cancer	0.00249	0.0314	CbGeAlD
Probenecid—PANX1—urethra—urinary bladder cancer	0.00232	0.0294	CbGeAlD
Probenecid—CYP3A4—Etoposide—urinary bladder cancer	0.00228	0.0029	CbGbCtD
Probenecid—SLC2A9—renal system—urinary bladder cancer	0.00214	0.0271	CbGeAlD
Probenecid—CYP2C19—urine—urinary bladder cancer	0.00209	0.0264	CbGeAlD
Probenecid—SLC16A7—prostate gland—urinary bladder cancer	0.00186	0.0235	CbGeAlD
Probenecid—ABCC11—female reproductive system—urinary bladder cancer	0.00182	0.0229	CbGeAlD
Probenecid—SLC10A1—prostate gland—urinary bladder cancer	0.00173	0.0219	CbGeAlD
Probenecid—SLC2A9—female reproductive system—urinary bladder cancer	0.00172	0.0217	CbGeAlD
Probenecid—PANX1—vagina—urinary bladder cancer	0.00171	0.0216	CbGeAlD
Probenecid—Pollakiuria—Valrubicin—urinary bladder cancer	0.00166	0.0327	CcSEcCtD
Probenecid—CYP2C9—urine—urinary bladder cancer	0.00162	0.0204	CbGeAlD
Probenecid—CYP3A4—Doxorubicin—urinary bladder cancer	0.00155	0.00198	CbGbCtD
Probenecid—Haematuria—Valrubicin—urinary bladder cancer	0.00153	0.0301	CcSEcCtD
Probenecid—SLC10A1—seminal vesicle—urinary bladder cancer	0.00147	0.0185	CbGeAlD
Probenecid—ABCC6—renal system—urinary bladder cancer	0.0013	0.0165	CbGeAlD
Probenecid—ABCC5—prostate gland—urinary bladder cancer	0.0013	0.0164	CbGeAlD
Probenecid—SLC16A7—urethra—urinary bladder cancer	0.00124	0.0157	CbGeAlD
Probenecid—CYP3A4—urine—urinary bladder cancer	0.00123	0.0156	CbGeAlD
Probenecid—SLC10A1—renal system—urinary bladder cancer	0.00118	0.0149	CbGeAlD
Probenecid—SLC16A1—prostate gland—urinary bladder cancer	0.00118	0.0149	CbGeAlD
Probenecid—Anaemia—Valrubicin—urinary bladder cancer	0.00116	0.0228	CcSEcCtD
Probenecid—SLCO1C1—renal system—urinary bladder cancer	0.00111	0.014	CbGeAlD
Probenecid—PANX1—lymph node—urinary bladder cancer	0.00111	0.014	CbGeAlD
Probenecid—ABCC3—prostate gland—urinary bladder cancer	0.00109	0.0138	CbGeAlD
Probenecid—SLC22A11—renal system—urinary bladder cancer	0.00108	0.0136	CbGeAlD
Probenecid—SLC22A7—renal system—urinary bladder cancer	0.00105	0.0133	CbGeAlD
Probenecid—SLC16A7—female reproductive system—urinary bladder cancer	0.00101	0.0128	CbGeAlD
Probenecid—SLC2A9—lymph node—urinary bladder cancer	0.001	0.0127	CbGeAlD
Probenecid—SLC10A1—female reproductive system—urinary bladder cancer	0.000946	0.012	CbGeAlD
Probenecid—SLC22A2—renal system—urinary bladder cancer	0.000937	0.0118	CbGeAlD
Probenecid—SLC16A7—vagina—urinary bladder cancer	0.000916	0.0116	CbGeAlD
Probenecid—ABCC4—prostate gland—urinary bladder cancer	0.0009	0.0114	CbGeAlD
Probenecid—SLC22A8—prostate gland—urinary bladder cancer	0.000893	0.0113	CbGeAlD
Probenecid—Alopecia—Mitomycin—urinary bladder cancer	0.000875	0.0172	CcSEcCtD
Probenecid—ABCC2—prostate gland—urinary bladder cancer	0.000871	0.011	CbGeAlD
Probenecid—SLC16A1—epithelium—urinary bladder cancer	0.000868	0.011	CbGeAlD
Probenecid—SLC22A11—female reproductive system—urinary bladder cancer	0.000864	0.0109	CbGeAlD
Probenecid—Pain—Carboplatin—urinary bladder cancer	0.000808	0.0159	CcSEcCtD
Probenecid—Body temperature increased—Valrubicin—urinary bladder cancer	0.000807	0.0159	CcSEcCtD
Probenecid—SLC16A1—renal system—urinary bladder cancer	0.000805	0.0102	CbGeAlD
Probenecid—Anaemia—Mitomycin—urinary bladder cancer	0.000796	0.0157	CcSEcCtD
Probenecid—Leukopenia—Mitomycin—urinary bladder cancer	0.000771	0.0152	CcSEcCtD
Probenecid—ABCC1—prostate gland—urinary bladder cancer	0.000767	0.0097	CbGeAlD
Probenecid—Body temperature increased—Carboplatin—urinary bladder cancer	0.000747	0.0147	CcSEcCtD
Probenecid—ABCC3—renal system—urinary bladder cancer	0.000743	0.00939	CbGeAlD
Probenecid—Pruritus—Valrubicin—urinary bladder cancer	0.000722	0.0142	CcSEcCtD
Probenecid—Dizziness—Valrubicin—urinary bladder cancer	0.000675	0.0133	CcSEcCtD
Probenecid—SLC22A5—prostate gland—urinary bladder cancer	0.000675	0.00853	CbGeAlD
Probenecid—Anorexia—Mitomycin—urinary bladder cancer	0.00067	0.0132	CcSEcCtD
Probenecid—SLC22A1—renal system—urinary bladder cancer	0.000662	0.00837	CbGeAlD
Probenecid—ABCC1—seminal vesicle—urinary bladder cancer	0.000649	0.0082	CbGeAlD
Probenecid—Vomiting—Valrubicin—urinary bladder cancer	0.000649	0.0128	CcSEcCtD
Probenecid—SLC16A1—female reproductive system—urinary bladder cancer	0.000645	0.00815	CbGeAlD
Probenecid—Dermatitis—Valrubicin—urinary bladder cancer	0.000643	0.0127	CcSEcCtD
Probenecid—ABCC5—vagina—urinary bladder cancer	0.000641	0.0081	CbGeAlD
Probenecid—Headache—Valrubicin—urinary bladder cancer	0.000639	0.0126	CcSEcCtD
Probenecid—SLCO1A2—renal system—urinary bladder cancer	0.000637	0.00806	CbGeAlD
Probenecid—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.000625	0.0123	CcSEcCtD
Probenecid—ABCC4—renal system—urinary bladder cancer	0.000613	0.00775	CbGeAlD
Probenecid—Decreased appetite—Mitomycin—urinary bladder cancer	0.000611	0.012	CcSEcCtD
Probenecid—SLC22A8—renal system—urinary bladder cancer	0.000608	0.00769	CbGeAlD
Probenecid—Nausea—Valrubicin—urinary bladder cancer	0.000606	0.0119	CcSEcCtD
Probenecid—Pain—Mitomycin—urinary bladder cancer	0.000601	0.0118	CcSEcCtD
Probenecid—ABCC3—female reproductive system—urinary bladder cancer	0.000595	0.00752	CbGeAlD
Probenecid—ABCC2—renal system—urinary bladder cancer	0.000594	0.00751	CbGeAlD
Probenecid—SLC16A7—lymph node—urinary bladder cancer	0.000592	0.00749	CbGeAlD
Probenecid—SLC22A5—seminal vesicle—urinary bladder cancer	0.000571	0.00722	CbGeAlD
Probenecid—Body temperature increased—Mitomycin—urinary bladder cancer	0.000556	0.011	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.000545	0.0107	CcSEcCtD
Probenecid—Haematuria—Thiotepa—urinary bladder cancer	0.000529	0.0104	CcSEcCtD
Probenecid—SLCO1C1—lymph node—urinary bladder cancer	0.00052	0.00658	CbGeAlD
Probenecid—ABCC1—urethra—urinary bladder cancer	0.000514	0.00649	CbGeAlD
Probenecid—ABCC4—female reproductive system—urinary bladder cancer	0.000491	0.00621	CbGeAlD
Probenecid—SLC22A1—vagina—urinary bladder cancer	0.000479	0.00606	CbGeAlD
Probenecid—ABCC2—female reproductive system—urinary bladder cancer	0.000475	0.00601	CbGeAlD
Probenecid—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.000465	0.00917	CcSEcCtD
Probenecid—Dizziness—Mitomycin—urinary bladder cancer	0.000465	0.00916	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.000462	0.00911	CcSEcCtD
Probenecid—SLC22A5—renal system—urinary bladder cancer	0.00046	0.00581	CbGeAlD
Probenecid—SLC22A5—urethra—urinary bladder cancer	0.000452	0.00571	CbGeAlD
Probenecid—Vomiting—Mitomycin—urinary bladder cancer	0.000447	0.00881	CcSEcCtD
Probenecid—CYP2C8—renal system—urinary bladder cancer	0.000445	0.00563	CbGeAlD
Probenecid—Haematuria—Gemcitabine—urinary bladder cancer	0.000445	0.00876	CcSEcCtD
Probenecid—Dermatitis—Mitomycin—urinary bladder cancer	0.000443	0.00873	CcSEcCtD
Probenecid—Headache—Mitomycin—urinary bladder cancer	0.00044	0.00868	CcSEcCtD
Probenecid—Alopecia—Thiotepa—urinary bladder cancer	0.00044	0.00867	CcSEcCtD
Probenecid—Nausea—Mitomycin—urinary bladder cancer	0.000418	0.00823	CcSEcCtD
Probenecid—ABCC5—lymph node—urinary bladder cancer	0.000415	0.00524	CbGeAlD
Probenecid—Anaemia—Thiotepa—urinary bladder cancer	0.0004	0.00789	CcSEcCtD
Probenecid—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.0004	0.00789	CcSEcCtD
Probenecid—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000396	0.0078	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.000395	0.00778	CcSEcCtD
Probenecid—Leukopenia—Thiotepa—urinary bladder cancer	0.000388	0.00764	CcSEcCtD
Probenecid—ABCC1—vagina—urinary bladder cancer	0.000379	0.00479	CbGeAlD
Probenecid—SLC16A1—lymph node—urinary bladder cancer	0.000377	0.00477	CbGeAlD
Probenecid—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.000375	0.00738	CcSEcCtD
Probenecid—Alopecia—Gemcitabine—urinary bladder cancer	0.00037	0.00729	CcSEcCtD
Probenecid—CYP2C19—vagina—urinary bladder cancer	0.00037	0.00467	CbGeAlD
Probenecid—SLC22A5—female reproductive system—urinary bladder cancer	0.000368	0.00466	CbGeAlD
Probenecid—Alopecia—Fluorouracil—urinary bladder cancer	0.000364	0.00717	CcSEcCtD
Probenecid—Flushing—Cisplatin—urinary bladder cancer	0.000362	0.00714	CcSEcCtD
Probenecid—CYP2C8—female reproductive system—urinary bladder cancer	0.000357	0.00451	CbGeAlD
Probenecid—ABCC3—lymph node—urinary bladder cancer	0.000348	0.0044	CbGeAlD
Probenecid—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.000347	0.00683	CcSEcCtD
Probenecid—Alopecia—Cisplatin—urinary bladder cancer	0.000345	0.00679	CcSEcCtD
Probenecid—Erythema multiforme—Etoposide—urinary bladder cancer	0.000338	0.00666	CcSEcCtD
Probenecid—Anorexia—Thiotepa—urinary bladder cancer	0.000337	0.00664	CcSEcCtD
Probenecid—Anaemia—Gemcitabine—urinary bladder cancer	0.000337	0.00664	CcSEcCtD
Probenecid—SLC22A5—vagina—urinary bladder cancer	0.000333	0.00421	CbGeAlD
Probenecid—Flushing—Etoposide—urinary bladder cancer	0.000332	0.00654	CcSEcCtD
Probenecid—Anaemia—Fluorouracil—urinary bladder cancer	0.000331	0.00653	CcSEcCtD
Probenecid—Leukopenia—Gemcitabine—urinary bladder cancer	0.000326	0.00643	CcSEcCtD
Probenecid—CYP2C8—vagina—urinary bladder cancer	0.000323	0.00408	CbGeAlD
Probenecid—Leukopenia—Fluorouracil—urinary bladder cancer	0.000321	0.00632	CcSEcCtD
Probenecid—CYP2C9—female reproductive system—urinary bladder cancer	0.000317	0.004	CbGeAlD
Probenecid—Alopecia—Etoposide—urinary bladder cancer	0.000316	0.00622	CcSEcCtD
Probenecid—Anaemia—Cisplatin—urinary bladder cancer	0.000314	0.00619	CcSEcCtD
Probenecid—ABCB1—prostate gland—urinary bladder cancer	0.000313	0.00396	CbGeAlD
Probenecid—Decreased appetite—Thiotepa—urinary bladder cancer	0.000307	0.00606	CcSEcCtD
Probenecid—Leukopenia—Cisplatin—urinary bladder cancer	0.000304	0.00599	CcSEcCtD
Probenecid—Pain—Thiotepa—urinary bladder cancer	0.000302	0.00596	CcSEcCtD
Probenecid—CYP3A4—renal system—urinary bladder cancer	0.000302	0.00381	CbGeAlD
Probenecid—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000297	0.00586	CcSEcCtD
Probenecid—ALB—lymph node—urinary bladder cancer	0.000297	0.00375	CbGeAlD
Probenecid—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000292	0.00576	CcSEcCtD
Probenecid—Anaemia—Etoposide—urinary bladder cancer	0.000288	0.00567	CcSEcCtD
Probenecid—ABCC4—lymph node—urinary bladder cancer	0.000287	0.00363	CbGeAlD
Probenecid—Anorexia—Gemcitabine—urinary bladder cancer	0.000284	0.00559	CcSEcCtD
Probenecid—Urticaria—Thiotepa—urinary bladder cancer	0.000281	0.00553	CcSEcCtD
Probenecid—Body temperature increased—Thiotepa—urinary bladder cancer	0.00028	0.00551	CcSEcCtD
Probenecid—Anorexia—Fluorouracil—urinary bladder cancer	0.000279	0.00549	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000279	0.00549	CcSEcCtD
Probenecid—Leukopenia—Etoposide—urinary bladder cancer	0.000279	0.00549	CcSEcCtD
Probenecid—ABCC2—lymph node—urinary bladder cancer	0.000278	0.00352	CbGeAlD
Probenecid—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000277	0.00546	CcSEcCtD
Probenecid—ABCB1—seminal vesicle—urinary bladder cancer	0.000265	0.00335	CbGeAlD
Probenecid—Anorexia—Cisplatin—urinary bladder cancer	0.000264	0.00521	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000261	0.00514	CcSEcCtD
Probenecid—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000261	0.00513	CcSEcCtD
Probenecid—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000259	0.00509	CcSEcCtD
Probenecid—Pain—Gemcitabine—urinary bladder cancer	0.000254	0.00501	CcSEcCtD
Probenecid—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000254	0.00501	CcSEcCtD
Probenecid—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000254	0.005	CcSEcCtD
Probenecid—Pruritus—Thiotepa—urinary bladder cancer	0.00025	0.00493	CcSEcCtD
Probenecid—Pain—Fluorouracil—urinary bladder cancer	0.00025	0.00493	CcSEcCtD
Probenecid—ABCC1—lymph node—urinary bladder cancer	0.000245	0.0031	CbGeAlD
Probenecid—Anorexia—Etoposide—urinary bladder cancer	0.000242	0.00477	CcSEcCtD
Probenecid—CYP3A4—female reproductive system—urinary bladder cancer	0.000242	0.00305	CbGeAlD
Probenecid—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000241	0.00476	CcSEcCtD
Probenecid—Decreased appetite—Cisplatin—urinary bladder cancer	0.000241	0.00475	CcSEcCtD
Probenecid—Pain—Cisplatin—urinary bladder cancer	0.000237	0.00467	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000236	0.00466	CcSEcCtD
Probenecid—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000235	0.00463	CcSEcCtD
Probenecid—Dizziness—Thiotepa—urinary bladder cancer	0.000234	0.00461	CcSEcCtD
Probenecid—Urticaria—Fluorouracil—urinary bladder cancer	0.000232	0.00458	CcSEcCtD
Probenecid—Pollakiuria—Epirubicin—urinary bladder cancer	0.000231	0.00456	CcSEcCtD
Probenecid—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000231	0.00456	CcSEcCtD
Probenecid—ABCB1—epithelium—urinary bladder cancer	0.00023	0.00291	CbGeAlD
Probenecid—Haematuria—Methotrexate—urinary bladder cancer	0.000227	0.00448	CcSEcCtD
Probenecid—Vomiting—Thiotepa—urinary bladder cancer	0.000225	0.00443	CcSEcCtD
Probenecid—Dermatitis—Thiotepa—urinary bladder cancer	0.000223	0.00439	CcSEcCtD
Probenecid—Headache—Thiotepa—urinary bladder cancer	0.000222	0.00436	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000221	0.00436	CcSEcCtD
Probenecid—Decreased appetite—Etoposide—urinary bladder cancer	0.000221	0.00435	CcSEcCtD
Probenecid—Body temperature increased—Cisplatin—urinary bladder cancer	0.000219	0.00432	CcSEcCtD
Probenecid—Pain—Etoposide—urinary bladder cancer	0.000217	0.00428	CcSEcCtD
Probenecid—SLC22A5—lymph node—urinary bladder cancer	0.000215	0.00272	CbGeAlD
Probenecid—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000215	0.00425	CcSEcCtD
Probenecid—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000214	0.00422	CcSEcCtD
Probenecid—ABCB1—renal system—urinary bladder cancer	0.000213	0.0027	CbGeAlD
Probenecid—Haematuria—Epirubicin—urinary bladder cancer	0.000213	0.00419	CcSEcCtD
Probenecid—Pruritus—Gemcitabine—urinary bladder cancer	0.00021	0.00415	CcSEcCtD
Probenecid—Nausea—Thiotepa—urinary bladder cancer	0.00021	0.00414	CcSEcCtD
Probenecid—ABCB1—urethra—urinary bladder cancer	0.00021	0.00265	CbGeAlD
Probenecid—Pruritus—Fluorouracil—urinary bladder cancer	0.000207	0.00408	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000205	0.00404	CcSEcCtD
Probenecid—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000204	0.00402	CcSEcCtD
Probenecid—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000202	0.00399	CcSEcCtD
Probenecid—Urticaria—Etoposide—urinary bladder cancer	0.000202	0.00398	CcSEcCtD
Probenecid—Body temperature increased—Etoposide—urinary bladder cancer	0.000201	0.00396	CcSEcCtD
Probenecid—Haematuria—Doxorubicin—urinary bladder cancer	0.000197	0.00388	CcSEcCtD
Probenecid—Dizziness—Fluorouracil—urinary bladder cancer	0.000193	0.00381	CcSEcCtD
Probenecid—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000189	0.00373	CcSEcCtD
Probenecid—Alopecia—Methotrexate—urinary bladder cancer	0.000189	0.00373	CcSEcCtD
Probenecid—Vomiting—Gemcitabine—urinary bladder cancer	0.000189	0.00373	CcSEcCtD
Probenecid—Dermatitis—Gemcitabine—urinary bladder cancer	0.000187	0.00369	CcSEcCtD
Probenecid—Hypersensitivity—Etoposide—urinary bladder cancer	0.000187	0.00369	CcSEcCtD
Probenecid—Headache—Gemcitabine—urinary bladder cancer	0.000186	0.00367	CcSEcCtD
Probenecid—Flushing—Epirubicin—urinary bladder cancer	0.000186	0.00366	CcSEcCtD
Probenecid—Vomiting—Fluorouracil—urinary bladder cancer	0.000186	0.00366	CcSEcCtD
Probenecid—Dermatitis—Fluorouracil—urinary bladder cancer	0.000184	0.00363	CcSEcCtD
Probenecid—Headache—Fluorouracil—urinary bladder cancer	0.000183	0.00361	CcSEcCtD
Probenecid—Pruritus—Etoposide—urinary bladder cancer	0.00018	0.00354	CcSEcCtD
Probenecid—Alopecia—Epirubicin—urinary bladder cancer	0.000177	0.00349	CcSEcCtD
Probenecid—Nausea—Gemcitabine—urinary bladder cancer	0.000177	0.00348	CcSEcCtD
Probenecid—Vomiting—Cisplatin—urinary bladder cancer	0.000176	0.00347	CcSEcCtD
Probenecid—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000175	0.00345	CcSEcCtD
Probenecid—Dermatitis—Cisplatin—urinary bladder cancer	0.000175	0.00344	CcSEcCtD
Probenecid—Nausea—Fluorouracil—urinary bladder cancer	0.000174	0.00342	CcSEcCtD
Probenecid—Anaemia—Methotrexate—urinary bladder cancer	0.000172	0.00339	CcSEcCtD
Probenecid—Flushing—Doxorubicin—urinary bladder cancer	0.000172	0.00339	CcSEcCtD
Probenecid—ABCB1—female reproductive system—urinary bladder cancer	0.000171	0.00216	CbGeAlD
Probenecid—Dizziness—Etoposide—urinary bladder cancer	0.000168	0.00331	CcSEcCtD
Probenecid—Leukopenia—Methotrexate—urinary bladder cancer	0.000167	0.00329	CcSEcCtD
Probenecid—Nausea—Cisplatin—urinary bladder cancer	0.000165	0.00324	CcSEcCtD
Probenecid—Alopecia—Doxorubicin—urinary bladder cancer	0.000164	0.00323	CcSEcCtD
Probenecid—Vomiting—Etoposide—urinary bladder cancer	0.000161	0.00318	CcSEcCtD
Probenecid—Anaemia—Epirubicin—urinary bladder cancer	0.000161	0.00318	CcSEcCtD
Probenecid—Dermatitis—Etoposide—urinary bladder cancer	0.00016	0.00315	CcSEcCtD
Probenecid—Headache—Etoposide—urinary bladder cancer	0.000159	0.00314	CcSEcCtD
Probenecid—Leukopenia—Epirubicin—urinary bladder cancer	0.000156	0.00308	CcSEcCtD
Probenecid—ABCB1—vagina—urinary bladder cancer	0.000155	0.00195	CbGeAlD
Probenecid—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000152	0.003	CcSEcCtD
Probenecid—Nausea—Etoposide—urinary bladder cancer	0.000151	0.00297	CcSEcCtD
Probenecid—Anaemia—Doxorubicin—urinary bladder cancer	0.000149	0.00294	CcSEcCtD
Probenecid—Anorexia—Methotrexate—urinary bladder cancer	0.000145	0.00286	CcSEcCtD
Probenecid—Leukopenia—Doxorubicin—urinary bladder cancer	0.000144	0.00285	CcSEcCtD
Probenecid—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000142	0.00281	CcSEcCtD
Probenecid—Anorexia—Epirubicin—urinary bladder cancer	0.000136	0.00267	CcSEcCtD
Probenecid—Decreased appetite—Methotrexate—urinary bladder cancer	0.000132	0.00261	CcSEcCtD
Probenecid—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000132	0.0026	CcSEcCtD
Probenecid—Pain—Methotrexate—urinary bladder cancer	0.00013	0.00256	CcSEcCtD
Probenecid—Anorexia—Doxorubicin—urinary bladder cancer	0.000126	0.00247	CcSEcCtD
Probenecid—Decreased appetite—Epirubicin—urinary bladder cancer	0.000124	0.00244	CcSEcCtD
Probenecid—Pain—Epirubicin—urinary bladder cancer	0.000122	0.0024	CcSEcCtD
Probenecid—Urticaria—Methotrexate—urinary bladder cancer	0.000121	0.00238	CcSEcCtD
Probenecid—Body temperature increased—Methotrexate—urinary bladder cancer	0.00012	0.00237	CcSEcCtD
Probenecid—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000115	0.00226	CcSEcCtD
Probenecid—Urticaria—Epirubicin—urinary bladder cancer	0.000113	0.00223	CcSEcCtD
Probenecid—Pain—Doxorubicin—urinary bladder cancer	0.000113	0.00222	CcSEcCtD
Probenecid—Body temperature increased—Epirubicin—urinary bladder cancer	0.000113	0.00222	CcSEcCtD
Probenecid—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000112	0.00221	CcSEcCtD
Probenecid—Pruritus—Methotrexate—urinary bladder cancer	0.000108	0.00212	CcSEcCtD
Probenecid—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000105	0.00207	CcSEcCtD
Probenecid—Urticaria—Doxorubicin—urinary bladder cancer	0.000105	0.00206	CcSEcCtD
Probenecid—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000104	0.00205	CcSEcCtD
Probenecid—Pruritus—Epirubicin—urinary bladder cancer	0.000101	0.00198	CcSEcCtD
Probenecid—Dizziness—Methotrexate—urinary bladder cancer	0.000101	0.00198	CcSEcCtD
Probenecid—ABCB1—lymph node—urinary bladder cancer	0.0001	0.00126	CbGeAlD
Probenecid—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.71e-05	0.00191	CcSEcCtD
Probenecid—Vomiting—Methotrexate—urinary bladder cancer	9.67e-05	0.00191	CcSEcCtD
Probenecid—Dermatitis—Methotrexate—urinary bladder cancer	9.58e-05	0.00189	CcSEcCtD
Probenecid—Headache—Methotrexate—urinary bladder cancer	9.53e-05	0.00188	CcSEcCtD
Probenecid—Dizziness—Epirubicin—urinary bladder cancer	9.42e-05	0.00186	CcSEcCtD
Probenecid—Pruritus—Doxorubicin—urinary bladder cancer	9.32e-05	0.00184	CcSEcCtD
Probenecid—Vomiting—Epirubicin—urinary bladder cancer	9.05e-05	0.00178	CcSEcCtD
Probenecid—Nausea—Methotrexate—urinary bladder cancer	9.04e-05	0.00178	CcSEcCtD
Probenecid—Dermatitis—Epirubicin—urinary bladder cancer	8.97e-05	0.00177	CcSEcCtD
Probenecid—Headache—Epirubicin—urinary bladder cancer	8.92e-05	0.00176	CcSEcCtD
Probenecid—Dizziness—Doxorubicin—urinary bladder cancer	8.71e-05	0.00172	CcSEcCtD
Probenecid—Nausea—Epirubicin—urinary bladder cancer	8.46e-05	0.00167	CcSEcCtD
Probenecid—Vomiting—Doxorubicin—urinary bladder cancer	8.38e-05	0.00165	CcSEcCtD
Probenecid—Dermatitis—Doxorubicin—urinary bladder cancer	8.3e-05	0.00164	CcSEcCtD
Probenecid—Headache—Doxorubicin—urinary bladder cancer	8.25e-05	0.00163	CcSEcCtD
Probenecid—Nausea—Doxorubicin—urinary bladder cancer	7.83e-05	0.00154	CcSEcCtD
Probenecid—ALB—Hemostasis—PLAU—urinary bladder cancer	1.12e-05	0.000136	CbGpPWpGaD
Probenecid—ABCC4—Hemostasis—KRAS—urinary bladder cancer	1.12e-05	0.000136	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—GSTM1—urinary bladder cancer	1.11e-05	0.000136	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—NCOR1—urinary bladder cancer	1.11e-05	0.000136	CbGpPWpGaD
Probenecid—SLC10A1—Metabolism—PTEN—urinary bladder cancer	1.11e-05	0.000136	CbGpPWpGaD
Probenecid—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	1.11e-05	0.000135	CbGpPWpGaD
Probenecid—SLC16A1—Metabolism—CREBBP—urinary bladder cancer	1.11e-05	0.000135	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.11e-05	0.000135	CbGpPWpGaD
Probenecid—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.11e-05	0.000135	CbGpPWpGaD
Probenecid—ALB—Metabolism—NAT2—urinary bladder cancer	1.1e-05	0.000134	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.1e-05	0.000134	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.09e-05	0.000133	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—GSTP1—urinary bladder cancer	1.09e-05	0.000133	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.09e-05	0.000132	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.09e-05	0.000132	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.07e-05	0.00013	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	1.07e-05	0.00013	CbGpPWpGaD
Probenecid—SLC10A1—Metabolism—EP300—urinary bladder cancer	1.06e-05	0.000129	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—NQO1—urinary bladder cancer	1.06e-05	0.000129	CbGpPWpGaD
Probenecid—ABCC1—Disease—MTHFR—urinary bladder cancer	1.06e-05	0.000129	CbGpPWpGaD
Probenecid—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.06e-05	0.000128	CbGpPWpGaD
Probenecid—ABCC1—Disease—TERT—urinary bladder cancer	1.05e-05	0.000128	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.05e-05	0.000128	CbGpPWpGaD
Probenecid—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.05e-05	0.000128	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	1.05e-05	0.000128	CbGpPWpGaD
Probenecid—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	1.04e-05	0.000126	CbGpPWpGaD
Probenecid—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.02e-05	0.000125	CbGpPWpGaD
Probenecid—ABCC5—Disease—CDKN1A—urinary bladder cancer	1.02e-05	0.000124	CbGpPWpGaD
Probenecid—ABCC5—Disease—PTEN—urinary bladder cancer	1.02e-05	0.000124	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—TYMS—urinary bladder cancer	1.01e-05	0.000123	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—NCOR1—urinary bladder cancer	1e-05	0.000122	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—GSTM1—urinary bladder cancer	1e-05	0.000122	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1e-05	0.000122	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—TYMP—urinary bladder cancer	9.97e-06	0.000121	CbGpPWpGaD
Probenecid—ABCC4—Hemostasis—TP53—urinary bladder cancer	9.95e-06	0.000121	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	9.93e-06	0.000121	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—NAT2—urinary bladder cancer	9.89e-06	0.00012	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	9.84e-06	0.00012	CbGpPWpGaD
Probenecid—ABCC5—Metabolism—PTGS2—urinary bladder cancer	9.78e-06	0.000119	CbGpPWpGaD
Probenecid—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	9.76e-06	0.000119	CbGpPWpGaD
Probenecid—ABCC5—Disease—EP300—urinary bladder cancer	9.71e-06	0.000118	CbGpPWpGaD
Probenecid—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	9.68e-06	0.000118	CbGpPWpGaD
Probenecid—ABCC1—Disease—FGFR3—urinary bladder cancer	9.68e-06	0.000118	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—NAT2—urinary bladder cancer	9.65e-06	0.000118	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—GPX1—urinary bladder cancer	9.6e-06	0.000117	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	9.58e-06	0.000117	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—RRM2—urinary bladder cancer	9.57e-06	0.000116	CbGpPWpGaD
Probenecid—ABCC4—Hemostasis—HRAS—urinary bladder cancer	9.52e-06	0.000116	CbGpPWpGaD
Probenecid—ALB—Metabolism—RRM2—urinary bladder cancer	9.51e-06	0.000116	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	9.5e-06	0.000116	CbGpPWpGaD
Probenecid—ABCC5—Disease—SRC—urinary bladder cancer	9.45e-06	0.000115	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—ERCC2—urinary bladder cancer	9.42e-06	0.000115	CbGpPWpGaD
Probenecid—ALB—Hemostasis—CREBBP—urinary bladder cancer	9.24e-06	0.000113	CbGpPWpGaD
Probenecid—ABCC3—Metabolism—PPARG—urinary bladder cancer	9.17e-06	0.000112	CbGpPWpGaD
Probenecid—ALB—Hemostasis—IGF1—urinary bladder cancer	9.13e-06	0.000111	CbGpPWpGaD
Probenecid—SLC16A1—Metabolism—PTGS2—urinary bladder cancer	9.09e-06	0.000111	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—NAT2—urinary bladder cancer	9.02e-06	0.00011	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	8.94e-06	0.000109	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—ENO2—urinary bladder cancer	8.86e-06	0.000108	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	8.86e-06	0.000108	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—MTHFR—urinary bladder cancer	8.86e-06	0.000108	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	8.85e-06	0.000108	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—TYMS—urinary bladder cancer	8.83e-06	0.000108	CbGpPWpGaD
Probenecid—ALB—Metabolism—ENO2—urinary bladder cancer	8.81e-06	0.000107	CbGpPWpGaD
Probenecid—ALB—Metabolism—HPGDS—urinary bladder cancer	8.81e-06	0.000107	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.81e-06	0.000107	CbGpPWpGaD
Probenecid—ABCC3—Metabolism—CREBBP—urinary bladder cancer	8.81e-06	0.000107	CbGpPWpGaD
Probenecid—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.76e-06	0.000107	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	8.73e-06	0.000106	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	8.73e-06	0.000106	CbGpPWpGaD
Probenecid—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	8.6e-06	0.000105	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	8.59e-06	0.000105	CbGpPWpGaD
Probenecid—ALB—Metabolism—GSTT1—urinary bladder cancer	8.54e-06	0.000104	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—RRM2—urinary bladder cancer	8.54e-06	0.000104	CbGpPWpGaD
Probenecid—ABCC5—Metabolism—PTEN—urinary bladder cancer	8.53e-06	0.000104	CbGpPWpGaD
Probenecid—ABCC5—Disease—MYC—urinary bladder cancer	8.46e-06	0.000103	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.46e-06	0.000103	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.44e-06	0.000103	CbGpPWpGaD
Probenecid—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.41e-06	0.000102	CbGpPWpGaD
Probenecid—ALB—Hemostasis—RHOA—urinary bladder cancer	8.36e-06	0.000102	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—GPX1—urinary bladder cancer	8.36e-06	0.000102	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—RRM2—urinary bladder cancer	8.33e-06	0.000101	CbGpPWpGaD
Probenecid—ABCC5—Disease—EGFR—urinary bladder cancer	8.28e-06	0.000101	CbGpPWpGaD
Probenecid—ABCC1—Disease—CREBBP—urinary bladder cancer	8.24e-06	0.0001	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—TYMS—urinary bladder cancer	8.23e-06	0.0001	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.23e-06	0.0001	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	8.21e-06	9.99e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	8.13e-06	9.91e-05	CbGpPWpGaD
Probenecid—ABCC5—Metabolism—EP300—urinary bladder cancer	8.13e-06	9.91e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	8.13e-06	9.91e-05	CbGpPWpGaD
Probenecid—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8e-06	9.74e-05	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	7.98e-06	9.72e-05	CbGpPWpGaD
Probenecid—SLC16A1—Metabolism—PTEN—urinary bladder cancer	7.93e-06	9.66e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	7.91e-06	9.63e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—ENO2—urinary bladder cancer	7.91e-06	9.63e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.86e-06	9.57e-05	CbGpPWpGaD
Probenecid—ABCC5—Disease—KRAS—urinary bladder cancer	7.82e-06	9.52e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—GPX1—urinary bladder cancer	7.79e-06	9.49e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—RRM2—urinary bladder cancer	7.79e-06	9.48e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—ENO2—urinary bladder cancer	7.72e-06	9.4e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—HPGDS—urinary bladder cancer	7.72e-06	9.4e-05	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	7.71e-06	9.39e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	7.67e-06	9.34e-05	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	7.67e-06	9.34e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	7.65e-06	9.31e-05	CbGpPWpGaD
Probenecid—SLC16A1—Metabolism—EP300—urinary bladder cancer	7.56e-06	9.21e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.55e-06	9.2e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—GSTT1—urinary bladder cancer	7.49e-06	9.12e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—RHOA—urinary bladder cancer	7.45e-06	9.08e-05	CbGpPWpGaD
Probenecid—ABCC3—Metabolism—PTGS2—urinary bladder cancer	7.21e-06	8.78e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—ENO2—urinary bladder cancer	7.21e-06	8.78e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	7.21e-06	8.78e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	7.19e-06	8.75e-05	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—PPARG—urinary bladder cancer	7.18e-06	8.75e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.17e-06	8.73e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—NQO1—urinary bladder cancer	7.14e-06	8.7e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—NQO1—urinary bladder cancer	7.1e-06	8.65e-05	CbGpPWpGaD
Probenecid—ALB—Hemostasis—IL2—urinary bladder cancer	7.01e-06	8.54e-05	CbGpPWpGaD
Probenecid—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.01e-06	8.53e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	6.99e-06	8.52e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.93e-06	8.44e-05	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—CREBBP—urinary bladder cancer	6.9e-06	8.4e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—ERBB2—urinary bladder cancer	6.9e-06	8.4e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.89e-06	8.39e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.89e-06	8.39e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—PTGS2—urinary bladder cancer	6.75e-06	8.22e-05	CbGpPWpGaD
Probenecid—ABCC5—Disease—HRAS—urinary bladder cancer	6.65e-06	8.1e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.58e-06	8.01e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—NQO1—urinary bladder cancer	6.37e-06	7.76e-05	CbGpPWpGaD
Probenecid—ALB—Hemostasis—EP300—urinary bladder cancer	6.29e-06	7.66e-05	CbGpPWpGaD
Probenecid—ABCC3—Metabolism—PTEN—urinary bladder cancer	6.29e-06	7.66e-05	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	6.28e-06	7.65e-05	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—PPARG—urinary bladder cancer	6.25e-06	7.62e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—NQO1—urinary bladder cancer	6.22e-06	7.58e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.18e-06	7.53e-05	CbGpPWpGaD
Probenecid—ALB—Hemostasis—SRC—urinary bladder cancer	6.12e-06	7.45e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.04e-06	7.36e-05	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	6.01e-06	7.32e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.01e-06	7.32e-05	CbGpPWpGaD
Probenecid—ABCC3—Metabolism—EP300—urinary bladder cancer	6e-06	7.3e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	5.96e-06	7.25e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.95e-06	7.24e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—GSTP1—urinary bladder cancer	5.92e-06	7.21e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—CDKN1A—urinary bladder cancer	5.9e-06	7.18e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—PTEN—urinary bladder cancer	5.88e-06	7.17e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—PPARG—urinary bladder cancer	5.83e-06	7.1e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—NQO1—urinary bladder cancer	5.81e-06	7.08e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.76e-06	7.02e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.73e-06	6.98e-05	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—PTGS2—urinary bladder cancer	5.65e-06	6.88e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.64e-06	6.87e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—EP300—urinary bladder cancer	5.61e-06	6.83e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	5.6e-06	6.82e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—TYMS—urinary bladder cancer	5.54e-06	6.74e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—TYMS—urinary bladder cancer	5.51e-06	6.7e-05	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	5.48e-06	6.67e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	5.47e-06	6.66e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	5.47e-06	6.66e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—SRC—urinary bladder cancer	5.46e-06	6.64e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—GSTM1—urinary bladder cancer	5.44e-06	6.63e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—NCOR1—urinary bladder cancer	5.44e-06	6.63e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.39e-06	6.57e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	5.32e-06	6.47e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—GPX1—urinary bladder cancer	5.24e-06	6.38e-05	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—EP300—urinary bladder cancer	5.22e-06	6.36e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—GPX1—urinary bladder cancer	5.21e-06	6.35e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—GSTP1—urinary bladder cancer	5.19e-06	6.32e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	5.15e-06	6.27e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.14e-06	6.26e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.13e-06	6.25e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—ERCC2—urinary bladder cancer	5.12e-06	6.23e-05	CbGpPWpGaD
Probenecid—ALB—Hemostasis—KRAS—urinary bladder cancer	5.07e-06	6.17e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—TYMS—urinary bladder cancer	4.94e-06	6.02e-05	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—PTEN—urinary bladder cancer	4.93e-06	6e-05	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	4.92e-06	5.99e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.92e-06	5.99e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—MYC—urinary bladder cancer	4.89e-06	5.95e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	4.89e-06	5.95e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	4.89e-06	5.95e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.85e-06	5.9e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	4.84e-06	5.89e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.82e-06	5.87e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—MTHFR—urinary bladder cancer	4.81e-06	5.86e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—EGFR—urinary bladder cancer	4.78e-06	5.82e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.77e-06	5.81e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.77e-06	5.81e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.75e-06	5.79e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.75e-06	5.79e-05	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—EP300—urinary bladder cancer	4.7e-06	5.72e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.69e-06	5.71e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—GPX1—urinary bladder cancer	4.68e-06	5.7e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.61e-06	5.62e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	4.59e-06	5.59e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	4.59e-06	5.58e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.57e-06	5.56e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—KRAS—urinary bladder cancer	4.52e-06	5.5e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.51e-06	5.49e-05	CbGpPWpGaD
Probenecid—ALB—Hemostasis—TP53—urinary bladder cancer	4.5e-06	5.48e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.48e-06	5.46e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.45e-06	5.42e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.45e-06	5.42e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	4.32e-06	5.26e-05	CbGpPWpGaD
Probenecid—ALB—Hemostasis—HRAS—urinary bladder cancer	4.31e-06	5.24e-05	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—PTEN—urinary bladder cancer	4.29e-06	5.23e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.27e-06	5.19e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.21e-06	5.13e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.19e-06	5.1e-05	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—EP300—urinary bladder cancer	4.09e-06	4.98e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—PTEN—urinary bladder cancer	4e-06	4.87e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.94e-06	4.79e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—PPARG—urinary bladder cancer	3.92e-06	4.78e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—PPARG—urinary bladder cancer	3.9e-06	4.75e-05	CbGpPWpGaD
Probenecid—ABCC1—Disease—HRAS—urinary bladder cancer	3.84e-06	4.68e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.83e-06	4.67e-05	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—EP300—urinary bladder cancer	3.81e-06	4.64e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	3.77e-06	4.59e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—CREBBP—urinary bladder cancer	3.75e-06	4.56e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—PPARG—urinary bladder cancer	3.5e-06	4.26e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.42e-06	4.16e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	3.36e-06	4.1e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.28e-06	4e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.2e-06	3.89e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.19e-06	3.89e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.09e-06	3.76e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—PTGS2—urinary bladder cancer	3.07e-06	3.74e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.07e-06	3.73e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.97e-06	3.62e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.94e-06	3.58e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.94e-06	3.58e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.81e-06	3.43e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.76e-06	3.36e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.75e-06	3.35e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.69e-06	3.28e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.69e-06	3.27e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—PTEN—urinary bladder cancer	2.68e-06	3.26e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.6e-06	3.16e-05	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—EP300—urinary bladder cancer	2.57e-06	3.12e-05	CbGpPWpGaD
Probenecid—ALB—Metabolism—EP300—urinary bladder cancer	2.55e-06	3.11e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.51e-06	3.06e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—PTEN—urinary bladder cancer	2.4e-06	2.92e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.34e-06	2.85e-05	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.29e-06	2.79e-05	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—EP300—urinary bladder cancer	2.24e-06	2.72e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.19e-06	2.67e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.11e-06	2.56e-05	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.09e-06	2.54e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.02e-06	2.46e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.66e-06	2.02e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.44e-06	1.76e-05	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.38e-06	1.68e-05	CbGpPWpGaD
